A new highly sensitive assay revealed that cell-penetrating peptides improve cytosolic delivery through increased membrane binding, not enhanced endosomal escape — fundamentally changing how drug delivery scientists should design peptide carriers.
Paradigm shift: membrane, not endosomeThe SLEEQ assay definitively showed that cell-penetrating peptides enhance delivery by increasing membrane association, not endosomal escape — changing the design strategy for an entire field of drug delivery.
What the researchers found
The SLEEQ (Split Luciferase Endosomal Escape Quantification) assay was developed as a highly sensitive tool for quantifying cytosolic delivery of CPP-protein fusions. Testing multiple widely studied cell-penetrating peptides revealed that positively charged CPPs enhanced cytosolic delivery by increasing non-specific cell membrane association — not by improving endosomal escape efficiency.
This is a paradigm-changing finding: the field had largely assumed CPPs work by facilitating endosomal escape (helping cargo leave endosomal compartments to reach the cytosol). Instead, CPPs simply increase the total amount of cargo that associates with cells, and the same proportion escapes endosomes regardless of CPP presence.
Why it matters
Billions of research dollars have been spent trying to improve endosomal escape as the key bottleneck in intracellular drug delivery. This study suggests that for CPPs, the bottleneck is actually membrane association — getting more cargo to stick to cells in the first place. This fundamentally redirects drug delivery research: instead of engineering better endosomal escape, scientists should focus on enhancing membrane binding for CPP-based therapies.
The numbers in context
Multiple CPPs tested; positively charged CPPs showed increased membrane association; SLEEQ assay developed
How the study worked
Researchers developed the SLEEQ assay using split luciferase complementation to directly and quantitatively measure cytosolic delivery of protein cargo. Multiple widely studied CPPs were fused to a model protein and tested in cell culture. The assay distinguished between total cellular uptake and actual cytosolic delivery, allowing researchers to calculate endosomal escape efficiency independently of uptake. This resolved conflicting results from previous less sensitive and indirect assays.
Who was studied
Cell cultures with multiple CPP-protein fusions
What this study cannot tell us
All experiments were performed in cell culture, which may not capture the complexity of in vivo delivery where protein corona formation, immune clearance, and tissue barriers are present. Only one model protein cargo was tested — different cargo types (nucleic acids, smaller peptides) may interact differently with CPPs. The SLEEQ assay requires genetic modification of cells, which limits its application to laboratory settings. The findings may not apply to all CPP types or all cell types.
How to read the evidence
Published in Nature Communications, this is a high-impact mechanistic study with a novel quantitative assay. The findings are based on rigorous in vitro experiments, though in vivo validation would strengthen the conclusions. The SLEEQ assay represents a significant methodological advance.
When this study was published
Published in 2021, this study has already influenced how CPP-based delivery systems are designed and evaluated. The SLEEQ assay has been adopted by other research groups.
The bigger picture
This study is a cornerstone for the intracellular drug delivery field because it provides a reliable assay to resolve long-standing mechanistic debates. The SLEEQ assay can be applied beyond CPPs — to lipid nanoparticles, polymeric carriers, and any other delivery system claiming cytosolic delivery. By establishing that CPPs work through membrane association rather than endosomal escape, it reshapes the design principles for an entire class of delivery systems used in gene therapy, peptide therapeutics, and RNA medicine.
Questions still open
- Should drug delivery research shift focus from endosomal escape to membrane binding optimization for CPP-based systems?
- Does this mechanism hold true for CPP delivery of nucleic acids and small molecules, not just proteins?
- Can the SLEEQ assay be adapted to measure endosomal escape efficiency of lipid nanoparticles used in mRNA vaccines?
Common questions
How do cell-penetrating peptides actually get drugs inside cells?
Why does this matter for drug development?
Read the original research
Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay.
Nature communications, 12(1), 3721
Citation
Teo, Serena L Y; Rennick, Joshua J; Yuen, Daniel; Al-Wassiti, Hareth; Johnston, Angus P R; Pouton, Colin W. (2021). Unravelling cytosolic delivery of cell penetrating peptides with a quantitative endosomal escape assay.. Nature communications, 12(1), 3721. https://doi.org/10.1038/s41467-021-23997-x